Drug Trial Radar · NCT06111235
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
367
Actual
Start
Dec 14, 2023
Primary completion
Nov 2026
Study completion Feb 2029
Sponsor
- Lead sponsor
- CG Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Conditions
- Non Muscle Invasive Bladder Cancer
- Urologic Cancer
- Bladder Cancer
- Urothelial Carcinoma
Interventions
Cretostimogene GrenadenorepvecDrug
Engineered Oncolytic Adenovirus
n-dodecyl-B-D-maltosideOther
Transduction-enhancing agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence Free Survival (RFS)Time frame: 29 months
Locations
95 sites in 2 countries. Site status is shown where the registry gives one.
Urology Centers of Alabama PC
Homewood, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic
Scottsdale, Arizona
Arizona Institute of Urology PLLC
Tucson, Arizona
Arkansas Urology PA
Little Rock, Arkansas
Michael G. Oefelein MD Clinical Trials
Bakersfield, California
USC/Keck Department of Urology
Los Angeles, California
Tower Urology
Los Angeles, California
Sun Kim Urology
Orange, California
University of California Irvine Medical Center (UCIMC)
Orange, California
University of California Davis Cancer Center
Sacramento, California
Stanford University School of Medicine
Stanford, California
Colorado Clinical Research
Aurora, Colorado
Urology Associates, PC
Lone Tree, Colorado
Hartford HealthCare Medical Group
Hartford, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Advanced Urology Institute
Daytona Beach, Florida
Mayo Clinic Cancer Center
Jacksonville, Florida
Lakeland Regional Health
Lakeland, Florida
Advanced Urology Institute, LLC
Largo, Florida
University of Miami
Miami, Florida
Emory Winship Cancer Center
Atlanta, Georgia
Velocity Clinical Research- Savanah Urological Associates
Savannah, Georgia
Rush University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
UroPartners LLC
Glenview, Illinois
Duly Health and Care
Lisle, Illinois
Urology of Indiana, LLC
Carmel, Indiana
Urology of Indiana
Greenwood, Indiana
Urology Center of Iowa Research
West Des Moines, Iowa
The University of Kansas Cancer Center
Westwood, Kansas
Wichita Urology Group
Wichita, Kansas
First Urology, PSC
Louisville, Kentucky
Southern Urology
Lafayette, Louisiana
Regional Urology, LLC
Shreveport, Louisiana
Chesapeake Urology Associates, LLC
Baltimore, Maryland
Johns Hopkins Hospital Green Spring Station
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Cancer Center at Beth Israel Deaconess Medical Center - Research
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.